Use of levocetirizine and montelukast to treat rhinosinusitis and nasal polyposis

Abstract

The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient. The combination can be useful during and following radiation exposure to ameliorate the inflammatory response.

What is claimed is: 
     
         1 . A method of treating a patient having rhinosinusitis with nasal polyposis, the method comprising administering to the patient an effective amount of a combination of levocetirizine and montelukast. 
     
     
         2 . The method of  claim 1 , wherein the combination is administered at the onset of symptoms. 
     
     
         3 . The method of  claim 1 , wherein the combination is administered in a sequential manner. 
     
     
         4 . The method of  claim 1 , wherein the combination is administered in a substantially simultaneous manner. 
     
     
         5 . The method of  claim 1 , wherein the condition is caused by a viral infection. 
     
     
         6 . The method of  claim 5 , wherein the viral infection is caused by a virus selected from the group consisting of: rhinovirus, coronavirus, influenza, human parainfluenza virus, human respiratory syncytial virus, adenovirus, enterovirus, and metapneumovirus or Epstein Barr virus. 
     
     
         7 . The method of  claim 1 , wherein the combination is administered to the patient by one or more of the routes consisting of enteral, intravenous, intraperitoneal, inhalation, intramuscular, subcutaneous and oral. 
     
     
         8 . The method of  claim 1 , wherein the levocetirizine and montelukast are administered by the same route. 
     
     
         9 . The method of  claim 1 , wherein the combination further comprising a steroid. 
     
     
         10 . The method of  claim 1 , wherein the rhinosinusitis is caused by bacterial infection. 
     
     
         11 . The method of  claim 10 , wherein the bacterial infection is caused by a bacteria selected from the group consisting of  Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus , anaerobic bacteria, and gram negative bacteria. 
     
     
         12 . A method of treating a patient having rhinosinusitis, the method comprising administering to the patient an effective amount of a combination of levocetirizine and montelukast. 
     
     
         13 . The method of  claim 12 , wherein the combination is administered at the onset of symptoms. 
     
     
         14 . The method of  claim 12 , wherein the combination is administered in a sequential manner. 
     
     
         15 . The method of  claim 12 , wherein the combination is administered in a substantially simultaneous manner. 
     
     
         16 . The method of  claim 12 , wherein the rhinosinusitis is bacterial, viral, or fungal. 
     
     
         17 . A method of treating a patient having nasal polyposis, the method comprising administering to the patient an effective amount of a combination of levocetirizine and montelukast. 
     
     
         18 . The method of  claim 17 , wherein the combination is administered at the onset of symptoms. 
     
     
         19 . The method of  claim 17 , wherein the combination is administered in a sequential manner. 
     
     
         20 . The method of  claim 17 , wherein the combination is administered in a substantially simultaneous manner.